![Medical Writing in Canada Presented at AMWA National Conference October 25, 2008, Louisvile, KY Amanda Strong [email_address] 514.239.2736 www.medicalcommunications.ca](https://image.slidesharecdn.com/medicalwritingcanada-amwa2008-091015103244-phpapp01/85/Medical-Writing-Canada-1-320.jpg)
![Pharma in Canada ,[object Object],[object Object],[object Object],[object Object],[object Object],Source: Industry Canada. Canadian pharmaceutical Industry Profile. http://strategis.ic.gc.ca/epic/site/lsg-pdsv.nsf/en/h_hn00021e.html](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (7)
Similar to Medical Writing Canada
Similar to Medical Writing Canada (20)
Recently uploaded
Recently uploaded (20)
Medical Writing Canada
- 1. Medical Writing in Canada Presented at AMWA National Conference October 25, 2008, Louisvile, KY Amanda Strong [email_address] 514.239.2736 www.medicalcommunications.ca
- 3. Pharma in Canada Source: Industry Canada. Canadian pharmaceutical Industry Profile. http://strategis.ic.gc.ca/epic/site/lsg-pdsv.nsf/en/h_hn00021e.html
- 4. Pharma in Canada Source: 2005 drugstore and hospital purchases audit performed by IMS Health Top 10 leading pharmaceutical companies in Canada 3.2 552 Montreal Bristol-Myers Squibb 10 3.5 602 Montreal Merck Frosst 9 3.7 625 Quebec Sanofi-Aventis 8 3.8 647 Toronto Novartis 7 4.0 675 Montreal Wyeth 6 5.6 950 Toronto Apotex 5 5.8 996 Toronto GlaxoSmithKline 4 6.5 1,106 Toronto Johnson & Johnson 3 6.6 1,121 Montreal AstraZeneca 2 13.4 2,288 Montreal Pfizer 1 Market Share (%) Total Sales ($Millions) R&D Location Leading Companies Rank
- 5. Pharma in Canada Top 10 leading therapeutic classes (2005) Source: 2005 drugstore and hospital purchases audit performed by IMS Health 37.5 161.1 Proton Pump Inhibitor Pantoloc 10 17.3 178.7 Hematopoietic Agent Eprex 9 0.2 186.1 Systemic Anti-Arthritic Celebrex 8 17.5 198.6 Tranquilizer Zyprexa 7 8.3 227.5 Antidepressant Paxil 6 40.6 234.9 ACE Inhibitor Altace 5 17.1 250.2 Calcium Channel Blocker Norvasc 4 42.3 291.4 Cholesterol Reducer Zocor 3 1.4 424.3 Proton Pump Inhibitor Losec 2 32.5 625.7 Cholesterol Reducer Lipitor 1 2005 Growth (%) Total Sales ($ Millions) Therapeutic Subclass Leading Products Rank
- 7. Canadian Medical Writers Sectors of Employment of Medical Writers in Canada 10.2 ± 25.8 0.4 ± 2.1 Other 1.4 ± 4.6 4.3 ± 20.9 Non-governmental Organization 5.2 ± 11.5 0.2 ± 1.0 Governmental Organization 3.0 ± 9.7 4.3 ± 20.9 Research/Education Organization 6.2 ± 22.3 8.7 ± 28.8 Contract Research Organization 3.4 ± 7.9 4.3 ± 20.9 Healthcare Organization 22.9 ± 32.0 13.0 ± 34.4 Communication or Marketing 14.6 ± 26.4 12.4 ± 32.8 Journal or Publisher 1.7 ± 9.3 0 ± 0 Patient/Disease Association 1.3 ± 4.9 4.3 ± 20.9 Professional Association 24.5 ± 33.0 43.3 ± 50.4 Industry 5.2 ± 11.7 4.6 ± 18.9 Academia Freelance Employed
- 8. Canadian Medical Writers Yearly Income and Average Hours Worked per Week Source: 2008 AMWA Canada Salary Survey 26.2 – 33.8 37.1 – 40.2 95% CI 2, 45 30, 50 Min, Max 30.0 39.0 Median 30.0 ± 9.9 (22.5 ± 8.1 billable) 38.7 ± 3.7 Mean (± SD) Hours worked $48,223 – $76,740 $67,913 – $91,135 95% CI $1,000, $150,000 $40,000, $135,000 Min, Max $67,000 $75,000 Median $62,482 ± $36,044 $79,524 ± $25,508 Mean (± SD) Income Freelance Salary
- 13. Writing
Editor's Notes
- The pharmaceutical industry is involved in producing prescription and non-prescription drugs, including biopharmaceuticals. More than 22 000 drug products are available in Canada and the pharmaceutical industry is one of the most profitable in Canada, ranked #8 worldwide in market sales with an 8% annual growth rate. Drug costs are the single largest healthcare cost in Canada, behind hospitals and ahead of physicians, and its proportion is increasing every year. In 2005, about bout 18% of total health expenditures were pharmaceutical purchases. Biopharmaceuticals are a growing segment of the pharmaceutical market. In contrast to traditional pharmaceuticals that are chemicals, biologics are made by using living biological systems to modify large molecules, like proteins and hormones.
- Brand name drugs account for most sales in Canada (84% in 2005), most of which are developed and manufactured by foreign-owned multi-nationals like Merck-Frosst, Novartis, or Pfizer. The Canadian offices for most of these companies are located in the greater Montreal or Toronto areas. However biopharmaceutical companies tend to cluster in Montreal and Calgary. Brand-name companies are involved in the whole lifecycle of a drug, from development to market, and own (or license) the patents on a drug. Research and development (R&D) of a pharmaceutical is expensive and time-consuming. It typically takes between 10 to 15 years for a drug to reach market, at an estimated cost of $605 million USD for traditional chemical-based pharmaceuticals and $559 million USD for biopharmaceuticals (2005 costs). That does not include operating or marketing costs. Here are the top 10 leading pharmaceutical companies in Canada, according to a 2005 drugstore and hospital purchases audit performed by IMS Health:
- In 2005, 14% of drugs sold in Canada were cardiovascular agents. This class includes drugs used to treat high blood pressure (hypertension), heart failure, arrhythmia and angina, as well as anticoagulants and similar medications. The next largest class of drug sales in Canada was the psychotherapeutics (10%). These are drugs used to treat mental illness, such as depression, anxiety, schizophrenia and bipolar disorder. Cholesterol agents represented 9% of drugs sold in Canada, followed by anti-spasmodics (drugs that reduce muscle spasms or cramping; 8%) and anti-cancer agents (7%). Here are the top 10 leading prescription drug (brand name products), according to a 2005 drugstore and hospital purchases audit performed by IMS Health. Keep in mind that these are 2005 figures. In the pharmaceutical industry, ‘market position’ of a brand can change fairly rapidly as new drugs are introduced into the marketplace and long-term adverse event profiles of existing drugs become known.